Quantinno Capital Management LP Purchases 17,337 Shares of Cencora, Inc. (NYSE:COR)

Quantinno Capital Management LP increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 69.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,175 shares of the company's stock after purchasing an additional 17,337 shares during the quarter. Quantinno Capital Management LP's holdings in Cencora were worth $9,476,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. JFS Wealth Advisors LLC lifted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the period. Banque Transatlantique SA bought a new position in shares of Cencora in the fourth quarter worth about $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its holdings in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares during the last quarter. Finally, Kentucky Trust Co bought a new position in shares of Cencora in the fourth quarter worth about $33,000. Institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. This trade represents a 9.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Trading Up 0.7%

NYSE:COR traded up $2.15 on Monday, reaching $292.37. 1,553,490 shares of the stock traded hands, compared to its average volume of 1,544,787. The firm has a market capitalization of $56.70 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company's 50 day moving average is $279.87 and its 200-day moving average is $255.76.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.80 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Analysts Set New Price Targets

A number of research firms have recently commented on COR. Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Citigroup increased their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upped their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.